Clinical Trial Detail

NCT ID NCT03546582
Title SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma (KEYSTROKE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors RTOG Foundation, Inc.
Indications

head and neck squamous cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.